Suppr超能文献

KIF6基因多态性rs20455对伊朗南部100例患者冠心病风险及他汀类药物治疗效果的影响

Impact of KIF6 Polymorphism rs20455 on Coronary Heart Disease Risk and Effectiveness of Statin Therapy in 100 Patients from Southern Iran.

作者信息

Hamidizadeh Leila, Haji Hosseini Baghdad Abadi Reza, Babaee Baigi Mohammad Ali, Dastsooz Hassan, Khazaei Nejhad Ali, Fardaei Majid

机构信息

Department of Biology, Payame Noor University, Tehran, Iran.

Department of Cardiology, Shiraz University of Medical Science, Shiraz, Iran.

出版信息

Arch Iran Med. 2015 Oct;18(10):683-7.

Abstract

BACKGROUND

The purpose of this study was to investigate the association between Trp719Arg (rs20455) and Coronary Heart Disease (CHD), and also Coronary Heart Disease reduction in individuals with this SNP during statin therapy in southern Iran. It has been shown that rs20455, which could affect the function of kinesin protein, is associated with Coronary Heart Disease and could be an effective factor for patients who take statin therapy.

METHODS

Patients and control individuals were genotyped for rs20455 Single Nucleotide Polymorphism (SNP) using ARMS PCR (Amplification Refractory Mutation System Polymerase Chain Reaction) and RFLP (Restriction Fragment Length Polymorphism) analysis. The effect of kinesin family member 6 (KIF6) on statin therapy was also examined among patients who had a history of one or two heart attacks.

RESULTS

It was found that rs20455 had a significant association with Coronary Heart Disease (Odds Ratio [OR] 3.17, 95% Confidence Interval [CI] 1.68 to 5.98). In addition, statin therapy was more effective in rs20455 carriers than non-carriers, with 80% of the carriers showed positive response to this treatment.

CONCLUSIONS

Trp 719Arg have an effect on development of Coronary Heart Disease but it is very useful for statin therapy. Overall, individuals with this Single Nucleotide Polymorphism can take statin therapy to prevent the catastrophic consequences of Coronary Heart Disease.

摘要

背景

本研究旨在调查色氨酸719精氨酸(rs20455)与冠心病(CHD)之间的关联,以及在伊朗南部接受他汀类药物治疗的携带该单核苷酸多态性(SNP)个体中冠心病的减少情况。研究表明,可能影响驱动蛋白功能的rs20455与冠心病相关,并且可能是接受他汀类药物治疗患者的一个有效因素。

方法

使用扩增阻滞突变系统聚合酶链反应(ARMS PCR)和限制性片段长度多态性(RFLP)分析对患者和对照个体进行rs20455单核苷酸多态性基因分型。在有过一次或两次心脏病发作史的患者中,还研究了驱动蛋白家族成员6(KIF6)对他汀类药物治疗的影响。

结果

发现rs20455与冠心病有显著关联(优势比[OR] 3.17,95%置信区间[CI] 1.68至5.98)。此外,他汀类药物治疗对rs20455携带者比非携带者更有效,80%的携带者对该治疗表现出阳性反应。

结论

色氨酸719精氨酸对冠心病的发展有影响,但对他汀类药物治疗非常有用。总体而言,携带这种单核苷酸多态性的个体可以接受他汀类药物治疗以预防冠心病的灾难性后果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验